drug · antibody

EVKEEZA

updated 3mo ago

by $REGN REGENERON PHARMACEUTICALS, INC.🔗 ChEMBL

community read0 votes

🐶 often sniffed alongside

top 2

Antibody drug with a maximum clinical stage of Approval (across all indications), with 4 approved and 2 investigational indications.

targets

Angiopoietin-related protein 3

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

brand

EVKEEZA

trade names

Evkeeza

generic

EVINACUMAB-DGNB

MOA

12.1 Mechanism of Action Evinacumab-dgnb is a recombinant human monoclonal antibody that binds to and inhibits ANGPTL3. ANGPTL3 is a member of the angiopoietin-like protein family that is expressed primarily in the liver and plays a role in the regulation of lipid metabolism by inhibiting lipoprotein lipase (LPL) and endothelial lipase (EL). Evinacumab-dgnb inhibition of ANGPTL3 leads to reduction in LDL-C, high-density lipoprotein cholesterol (HDL-C), and triglycerides (TG). Evinacumab-dgnb reduces LDL-C independent of the presence of LDL receptor (LDLR) by promoting very low-density lipoprotein (VLDL) processing and clearance upstream of LDL formation. Evinacumab-dgnb blockade of ANGPTL3 lowers TG and HDL-C by rescuing LPL and EL activities, respectively.

indication

1 INDICATIONS AND USAGE EVKEEZA is indicated as an adjunct to diet and exercise and other low-density lipoprotein-cholesterol (LDL-C) lowering therapies to reduce LDL-C in adults and pediatric patients, aged 1 year and older, with homozygous familial hypercholesterolemia (HoFH). EVKEEZA is an angiopoietin-like 3 (ANGPTL3) inhibitor indicated as an adjunct to diet and exercise and other low-density lipoprotein-cholesterol (LDL-C) lowering therapies to reduce LDL-C in adults and pediatric patients, aged 1 year and older, with homozygous familial hypercholesterolemia (HoFH). ( 1 )

Data sources

ClinicalTrials.gov · OpenTargets

last refreshed 7m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

drug · antibody

save

EVKEEZA

updated 3mo ago

by $REGN REGENERON PHARMACEUTICALS, INC.🔗 ChEMBL

community read0 votes

🐶 often sniffed alongside

top 2

Antibody drug with a maximum clinical stage of Approval (across all indications), with 4 approved and 2 investigational indications.

targets

Angiopoietin-related protein 3

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

brand

EVKEEZA

trade names

Evkeeza

generic

EVINACUMAB-DGNB

MOA

indication

Data sources

ClinicalTrials.gov · OpenTargets

last refreshed 7m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

EVKEEZA

🐶 often sniffed alongside

targets

all catalysts(0)

News(0)

Report a data issue

comments(0)

EVKEEZA

🐶 often sniffed alongside

targets

all catalysts(0)

News(0)

Report a data issue

comments(0)